Natixis Advisors L.P. Boosts Stock Holdings in PerkinElmer, Inc. (NYSE:PKI)

Natixis Advisors L.P. lifted its stake in shares of PerkinElmer, Inc. (NYSE:PKIGet Rating) by 16.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,535 shares of the medical research company’s stock after purchasing an additional 3,117 shares during the period. Natixis Advisors L.P.’s holdings in PerkinElmer were worth $3,757,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. AlphaCrest Capital Management LLC boosted its holdings in shares of PerkinElmer by 116.8% during the 1st quarter. AlphaCrest Capital Management LLC now owns 5,489 shares of the medical research company’s stock worth $958,000 after purchasing an additional 2,957 shares during the last quarter. Harvest Fund Management Co. Ltd boosted its holdings in shares of PerkinElmer by 128.4% during the 1st quarter. Harvest Fund Management Co. Ltd now owns 765 shares of the medical research company’s stock worth $133,000 after purchasing an additional 430 shares during the last quarter. Private Advisor Group LLC boosted its holdings in shares of PerkinElmer by 21.8% during the 1st quarter. Private Advisor Group LLC now owns 3,380 shares of the medical research company’s stock worth $590,000 after purchasing an additional 606 shares during the last quarter. Cetera Advisor Networks LLC boosted its holdings in shares of PerkinElmer by 89.9% during the 1st quarter. Cetera Advisor Networks LLC now owns 3,417 shares of the medical research company’s stock worth $596,000 after purchasing an additional 1,618 shares during the last quarter. Finally, Blueshift Asset Management LLC boosted its holdings in shares of PerkinElmer by 72.0% during the 1st quarter. Blueshift Asset Management LLC now owns 2,326 shares of the medical research company’s stock worth $406,000 after purchasing an additional 974 shares during the last quarter. 77.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Credit Suisse Group assumed coverage on PerkinElmer in a report on Wednesday, August 24th. They set a “neutral” rating and a $175.00 target price on the stock. Robert W. Baird upped their price objective on PerkinElmer from $198.00 to $202.00 and gave the company an “outperform” rating in a report on Tuesday, August 2nd. Bank of America cut PerkinElmer from a “buy” rating to a “neutral” rating and set a $178.00 price objective on the stock. in a report on Tuesday, August 2nd. The Goldman Sachs Group decreased their price objective on PerkinElmer from $200.00 to $175.00 and set a “neutral” rating on the stock in a report on Thursday, July 14th. Finally, Barclays upped their price objective on PerkinElmer from $125.00 to $149.00 and gave the company an “underweight” rating in a report on Tuesday, August 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, PerkinElmer presently has a consensus rating of “Hold” and an average price target of $163.40.

PerkinElmer Stock Down 0.5 %

NYSE:PKI opened at $134.59 on Tuesday. The company has a quick ratio of 1.42, a current ratio of 2.02 and a debt-to-equity ratio of 0.63. The stock’s fifty day moving average is $145.99 and its two-hundred day moving average is $155.09. PerkinElmer, Inc. has a 52 week low of $130.65 and a 52 week high of $203.16. The stock has a market capitalization of $16.99 billion, a price-to-earnings ratio of 25.20, a price-to-earnings-growth ratio of 0.37 and a beta of 1.14.

PerkinElmer (NYSE:PKIGet Rating) last posted its quarterly earnings data on Monday, August 1st. The medical research company reported $2.32 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.31. PerkinElmer had a return on equity of 16.68% and a net margin of 13.21%. The business had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same quarter in the prior year, the company earned $2.83 earnings per share. The company’s revenue was up .1% on a year-over-year basis. Research analysts anticipate that PerkinElmer, Inc. will post 7.83 EPS for the current year.

PerkinElmer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 11th. Stockholders of record on Friday, October 21st will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.21%. The ex-dividend date is Thursday, October 20th. PerkinElmer’s dividend payout ratio is currently 5.24%.

Insider Transactions at PerkinElmer

In other news, insider Daniel R. Tereau sold 5,700 shares of the company’s stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $145.14, for a total transaction of $827,298.00. Following the sale, the insider now owns 13,380 shares of the company’s stock, valued at $1,941,973.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Daniel R. Tereau sold 5,700 shares of the company’s stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $145.14, for a total transaction of $827,298.00. Following the sale, the insider now owns 13,380 shares of the company’s stock, valued at $1,941,973.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider James M. Mock sold 5,025 shares of the company’s stock in a transaction on Friday, June 24th. The stock was sold at an average price of $145.49, for a total value of $731,087.25. Following the sale, the insider now directly owns 27,577 shares in the company, valued at approximately $4,012,177.73. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,898 shares of company stock valued at $2,083,263. 0.52% of the stock is currently owned by company insiders.

About PerkinElmer

(Get Rating)

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.

Read More

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKIGet Rating).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.